市场调查报告书
商品编码
1470428
心臟标记物市场:按产品、生物标记类型、最终用户、适应症 - 全球预测 2024-2030Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
心臟标记物市场规模预计2023年为38.1亿美元,预计2024年将达到41.6亿美元,2030年将达到72.9亿美元,复合年增长率为9.71%。
心臟标记是在血液中测量的物质或分子,用于诊断和监测各种心臟状况,特别是与心肌损伤和压力相关的状况。这些标记物通常用于医院和实验室等临床环境中,以帮助心血管疾病的诊断、预后和监测。尤其广泛应用于心肌梗塞和其他急性冠状动脉症候群的诊断。心血管疾病(CVD)准确、早期诊断的重要性日益增加,心臟标记市场的评估也逐渐提高。心血管疾病盛行率的上升和全球老年人口的增加正在推动心臟标记的市场需求。对照护现场检测的需求不断增长,医疗基础设施(包括设备齐全的实验室和训练有素的人员)的稳定发展正在推动全球产业的成长。然而,与心血管手术和解决方案相关的高价格正在影响市场采用。生物医学行业的进步,特别是诊断技术的进步,以及旨在促进预防性医疗保健的政府医疗保健倡议和计划,正在帮助扩大对心臟标誌物的需求,并为市场创造巨大的增长机会。
主要市场统计 | |
---|---|
基准年[2023] | 38.1亿美元 |
预测年份 [2024] | 41.6亿美元 |
预测年份 [2030] | 72.9亿美元 |
复合年增长率(%) | 9.71% |
产品:试剂和套件提供心臟特异性蛋白质的定性和定量评估
化学发光免疫测量(CLIA) 系统是先进的诊断仪器,可侦测敏感的心臟标记物,如肌钙蛋白、CK-MB 和肌红蛋白。这些装置利用发光基材,在目标抗原存在的情况下与特定酵素反应时发光。酵素结合免疫吸附检测法(ELISA)套件和设备对于心臟标记的检测和定量至关重要。这些测定依赖于产生可测量的比色变化的酶结合反应。 ELISA 系统在可扩展性方面非常弹性,并以其特异性和高灵敏度而闻名。免疫层析法是一种快速简单的诊断技术,利用颗粒透过毛细管作用沿着膜移动。抗体和抗原用于检测特定的生物标记物,例如心臟标记。萤光是一种使用萤光染料或标记物来检测特定抗体或抗原是否存在的技术,用于对心臟标记物进行更详细和特异性的分析。用于心臟标记检测的试剂和套件由针对各种分析平台优化的多种免疫测量组成。这些消耗品通常包括专为心臟特异性蛋白质的定性和定量评估而设计的抗体、抗原、缓衝液和基材。
生物标记类型:BNP 和 NT-proBNP 生物标记在心臟衰竭诊断和治疗中的采用率很高
BNP 和 NT-proBNP 是诊断和治疗心臟衰竭的生物标记。 BNP 从心室肌肉细胞中排放,以应对心臟衰竭典型的体液超负荷导致的室壁张力增加。当这些胜肽被检测到低水平时,它们对心臟风险和心臟衰竭具有强烈的阴性预测价值。相反,高水平表明不良心血管事件的风险增加。肌酸激酶-MB(CK-MB)是肌酸激酶(CK)的同功异构酵素,是诊断心肌梗塞(MI)的传统生物标记之一。它主要存在于心肌细胞中,当心肌细胞死亡时,其在血液中增加。高敏性C反应蛋白(Hs-CRP)是一种急性时相蛋白,也是一种指示全身性发炎的特异性发炎生物标记。它通常用于评估心臟疾病和其他心臟危险因素的风险。肌红蛋白是心肌损伤的早期标记物,但不具有特异性。它与更特异性的心臟标记(例如肌钙蛋白)结合使用最有用,可用于心肌梗塞的早期评估。肌钙蛋白 I 和 T 是调节蛋白,是心肌收缩装置的一部分,是心肌损伤的高度特异性和敏感的生物标记。
最终用户:在测试设施中更多地使用心臟标记物
实验室测试设施通常拥有先进的设备和熟练的员工,可以进行全面的测试。医院和独立诊断实验室是该细分市场的主要组成部分。他们提供准确、大容量的心臟标记检测服务,这对于诊断各种心血管疾病至关重要,包括心肌梗塞(心臟病发作)和急性冠状动脉症候群。即时护理 (POC) 检测设施包括急诊室、救护车、诊所和医生办公室。即时结果有助于快速做出临床决策,对于心臟紧急情况的处理至关重要。肌钙蛋白、BNP(B 型利钠胜肽)和 D-二聚体等心臟标记的 POC 检测彻底改变了心血管疾病的诊断和管理。心臟标记 POCT 系统设计简单、快速,可缩短急诊护理环境中决策的周转时间。
采用心臟标记物治疗郁血性心臟衰竭的可能性
在郁血性心臟衰竭(CHF)中,心臟标记对于诊断、预后和治疗非常重要。 B 型利钠胜肽(BNP) 和 N 端 BNP 前体 (NT-proBNP) 是用于确认疑似 CHF、将其与呼吸困难的其他原因区分开并评估严重程度的主要分子。 BNP 或 NT-proBNP 升高与心臟衰竭相关,这些标记可用于 CHF 患者的诊断和监测。在心肌梗塞 (MI) 中,肌钙蛋白 I、肌钙蛋白 T 和肌酸激酶 MB (CK-MB) 常被用作心肌梗塞的心臟标记。肌钙蛋白是检测心肌损伤的敏感且特异性的标记物。肌钙蛋白升高表示心肌梗塞,有助于诊断急性冠状动脉症候群。
区域洞察
美洲由于心血管疾病盛行率高、医疗设施发达、市场参与企业众多,市场格局显着。心臟病发病率的增加以及对早期诊断和早期治疗的强烈兴趣正在推动该地区对心臟标记检测的需求。此外,生物技术领域的进步和新型诊断技术的高采用率也促进了美国心臟标记市场的成长。欧洲心臟标记市场的成长是由更容易患心臟疾病等慢性疾病的人口老化所推动的。最先进的医疗设施、不断上涨的医疗成本以及有利的监管政策也支持了欧洲心臟标记市场的成长。此外,在心臟生物标记领域,多个主要市场参与企业和持续的研究活动正在进一步刺激市场成长。预计亚太地区心臟标记市场在预测期内将呈现显着成长。这是由于新兴经济体人口基数大、文明病盛行率上升以及医疗基础设施改善缓慢。
FPNV定位矩阵
FPNV定位矩阵对于评估心臟标记市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对心臟标记物市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该细分市场竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:包括新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:包括对未来技术、研发活动和突破性产品开发的智力见解。
1.心臟标记物市场的市场规模与预测是多少?
2.在心臟标记物市场预测期内,我们应该考虑投资哪些产品和应用?
3.心臟标记市场的技术趋势和法规结构是什么?
4.心臟标记市场主要厂商的市场占有率是多少?
5. 进入心臟标记物市场的合适形式和策略手段是什么?
[189 Pages Report] The Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024, at a CAGR 9.71% to reach USD 7.29 billion by 2030.
Cardiac markers are substances or molecules measured in the blood to diagnose and monitor various cardiac conditions, particularly those related to heart muscle damage or stress. These markers are often used in clinical settings, such as hospitals and laboratories, to assist in diagnosing, prognosis, and monitoring cardiovascular diseases. They are particularly widely used in the diagnosis of conditions such as myocardial infarction and other forms of acute coronary syndrome. With an increased emphasis on accurate and early diagnosis in cases of cardiovascular diseases (CVD), the cardiac markers market's valuation has been progressively escalating. The rising incidence of cardiovascular conditions and the growing global geriatric population fuel the market demand for cardiac markers. Rising demand for point-of-care testing and the steady development in healthcare infrastructure, including well-equipped labs and trained personnel, globally aids the industry's growth. However, High prices associated with cardiovascular procedures and solutions affect market adoption. The evolution of the biomedical industry, particularly diagnostic technologies, and government healthcare initiatives and programs aiming to foster preventative care are instrumental in escalating the demand for cardiac markers and creating a significant growth opportunity for the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.81 billion |
Estimated Year [2024] | USD 4.16 billion |
Forecast Year [2030] | USD 7.29 billion |
CAGR (%) | 9.71% |
Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins
Chemiluminescence immunoassay (CLIA) systems are sophisticated diagnostic instruments that detect high-sensitivity cardiac markers such as troponin, CK-MB, and myoglobin. These instruments utilize luminogenic substrates that emit light upon reaction with specific enzymes in the presence of the targeted antigen. Enzyme-linked immunosorbent assay (ELISA) kits and instruments are vital in detecting and quantifying cardiac markers. These assays rely on an enzyme-conjugate reaction that produces a measurable colorimetric change. ELISA systems offer flexibility in terms of scalability and are known for their specificity and high sensitivity. Immunochromatography is a rapid and simple diagnostic technique that utilizes the movement of particles along a membrane via capillary action. It involves using antibodies and antigens to detect specific biomarkers, such as cardiac markers. Immunofluorescence is a technique that uses fluorescent dyes or markers to detect the presence of specific antibodies or antigens, and it is employed for more detailed and specific analysis in the context of cardiac markers. Reagents and kits for cardiac marker detection comprise a wide range of immunoassays optimized for various analytical platforms. These consumables often include antibodies, antigens, buffers, and substrates specifically engineered for the qualitative and quantitative assessment of cardiac-specific proteins.
Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure
BNP and NT-proBNP are biomarkers for diagnosing and managing heart failure. BNP is discharged by ventricular myocytes in reaction to increased wall tension, typically due to fluid overload in heart failure. When found at low levels, these peptides have a strong negative predictive value for cardiac risk and heart failure. In contrast, elevated levels are indicative of an increased risk of adverse cardiovascular events. Creatine Kinase-MB (CK-MB) is an isoenzyme of creatine kinase (CK) and is one of the traditional biomarkers for diagnosing myocardial infarction (MI). It is found mainly in cardiac cells and increases in the blood following the death of heart muscle cells. High-sensitivity C-Reactive Protein (Hs-CRP) is an acute-phase protein and a non-specific inflammatory biomarker that can indicate systemic inflammation. It is often used to assess the risk of cardiac disease and other cardiac risk factors. Myoglobin is an early but non-specific marker of myocardial injury. It is most valuable when used alongside more specific cardiac markers, such as troponins, for the early assessment of myocardial infarction. Troponin I and T are regulatory proteins that are part of the cardiac muscle contractile apparatus and are highly specific and sensitive biomarkers for myocardial injury.
End-User: Significant utilization of cardiac marker in laboratory testing facilities
Laboratory testing facilities are typically equipped with sophisticated equipment and skilled personnel capable of performing a comprehensive range of tests. Hospitals and independent diagnostic labs are the primary constituents of this sector. They offer accurate and high-volume cardiac marker testing services, integral for diagnosing various cardiovascular conditions, including myocardial infarctions (heart attacks) and acute coronary syndromes. Point of Care (POC) testing facilities include emergency departments, ambulances, clinics, and physician offices. The immediacy of results allows for swift clinical decision-making, critical in managing cardiac emergencies. POC testing for cardiac markers, such as troponin, BNP (B-type natriuretic peptide), and D-dimer, has revolutionized diagnosing and managing cardiovascular diseases. POCT systems for cardiac markers are designed for simplicity and speed, reducing the turnaround time for decision-making in acute care settings.
Indication: Potential adoption of cardiac markers in congestive heart failure situations
In congestive heart failure (CHF) situations, cardiac markers are crucial in diagnosis, prognosis, and management. B-type natriuretic peptide (BNP) and N-terminal-pro BNP (NT-proBNP) are the primary biomarkers used to confirm suspected CHF, differentiate it from other causes of dyspnea, and assess the severity of the condition. Elevated levels of BNP or NT-proBNP are associated with heart failure, and these markers are used for both diagnosis and monitoring of CHF patients. In myocardial infarction (MI), Troponin I, Troponin T, and creatine kinase-MB (CK-MB) are commonly used cardiac markers for myocardial infarction. Troponins are sensitive and specific markers for detecting myocardial injury. Elevated levels of troponins indicate myocardial infarction and help in diagnosing acute coronary syndrome.
Regional Insights
The Americas has a significant market landscape in the cardiac marker market due to a high prevalence of cardiovascular diseases, well-established healthcare facilities, and major market players. The increasing incidence of heart attacks and the strong focus on early diagnosis and treatment are driving the demand for cardiac marker tests in this region. Moreover, advancements in the biotechnology sector and higher adoption rates for novel diagnostics methodologies contribute to America's cardiac marker market growth. Europe's market growth in the cardiac marker is propelled by the rising aging population, which is more prone to chronic diseases, including coronary heart disease. The availability of cutting-edge healthcare facilities, rising healthcare expenditures, and favorable regulatory policies also support the growth of the European cardiac marker market. Moreover, several key market players and ongoing research activities in the cardiac biomarkers space further stimulate market growth. The Asia-Pacific region is projected to show a significant cardiac marker market growth rate during the forecast period attributed to the large population base, the rising incidences of lifestyle diseases, and the gradual improvement in healthcare infrastructure across emerging economies.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Marker Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Marker Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomerieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Cardiac Marker Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Marker Market?
3. What are the technology trends and regulatory frameworks in the Cardiac Marker Market?
4. What is the market share of the leading vendors in the Cardiac Marker Market?
5. Which modes and strategic moves are suitable for entering the Cardiac Marker Market?